Nephrocare Health IPO GMP Today

GMP for Nephrocare Health IPO started at Rs 0 on 3 December 2025 and stood at Rs 35 on 15 December 2025. The sharpest single-day jump was from Rs 11 on 11 Dec 2025 to Rs 33 on 12 Dec 2025. The upward move through the subscription window usually reflects building demand across investor categories rather than a one-day spike.

Based on today's GMP, Nephrocare Health IPO listing price estimate is Rs 497.00 per share (issue price Rs 460.00 + GMP Rs 37.00).

Actual listing price will be known on 17 December 2025 when the stock lists on NSE/BSE.

At about 8.0% GMP, demand looks positive but not aggressive. Listing outcome will depend heavily on subscription data and market mood on listing day.

GMP is unofficial. Listing gain can differ on listing day.

GMP and subscription numbers often move together. When institutional and HNI demand is strong, grey market participants usually price in a higher premium. Current overall subscription for Nephrocare Health IPO is 14.08x. Compare this with the GMP trend to see if demand aligns. The GMP move around 12 Dec 2025 may reflect how the market reacted once the subscription window activity picked up after 10 Dec 2025.

See live figures on the Nephrocare Health IPO Subscription Status page.

Nephrocare Health IPO full details (financials, peers, review).

Nephrocare Health Services Ltd., founded in 2010, is India’s and Asia’s largest dialysis chain, providing complete dialysis care, including haemodialysis, home/mobile dialysis, and wellness programs. The company operates 519 clinics globally (51 internationally) and approximately 78% of its Indian clinics are located in Tier II and III cities. Nephrocare follows an asset-light model, partnering with major hospital chains like Max, Fortis, and Care Hospitals. The company has a track record of growth, profitability, and positive returns since recovering from losses in FY23.